Physician profile
Christopher R Rose
NPI 1619075520
$11,518.71
in general payments reported to CMS, 2019-2025
30 companies · $1,963 in 2025
The $1,963 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $557 · 2021: $512 · 2022: $667 · 2023: $839 · 2024: $6,633 · 2025: $1,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,807 · Food and Beverage: $2,715 · Travel and Lodging: $1,734 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,807.00 |
| Food and Beverage | $2,714.55 |
| Travel and Lodging | $1,734.19 |
| Education | $179.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $6,200.36 | 2019-2024 | |
| Inspire Medical Systems, INC. | $2,889.07 | 2019-2025 | Inspire |
| Harmony Biosciences LLC | $558.62 | 2020-2025 | |
| Lilly USA, LLC | $455.83 | 2020-2025 | Emgality, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.77 | 2020-2022 | |
| Corcept Therapeutics | $118.80 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $116.64 | 2022-2025 | Quviviq |
| Abbvie INC. | $114.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.89 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $95.39 | 2019-2022 | |
| Sanofi Pasteur INC. | $84.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.78 | 2021 | |
| Glaxosmithkline, LLC. | $72.46 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $59.62 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $50.40 | 2022-2024 | Ozempic, Rybelsus |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.60 | 2019-2025 | Evenity |
| Allergan, INC. | $40.91 | 2020 | |
| Amarin Pharma, INC. | $36.63 | 2020-2022 | |
| Fisher & Paykel Healthcare INC | $32.08 | 2024 | Fisher & Paykel Healthcare |
| Gilead Sciences, INC. | $29.59 | 2020-2021 | |
| Horizon Therapeutics Plc | $25.48 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.47 | 2024 | Gvoke Hypopen |
| Eisai INC. | $22.47 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $22.34 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.29 | 2023 | Lifevest |
| Arbor Pharmaceuticals, INC. | $18.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.39 | 2022 | |
| Resmed Corp | $13.17 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.34 | 2021 | |
| Abbott Laboratories | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.